Michel Dahan, SVP, Chief Business Officer at Akebia Therapeutics, Inc. (AKBA), sold 5,000 shares at $19.30 ($97K) on 2017-09-28, disclosed to the SEC on 2017-10-02.
Open-market sale of $96k AKBA by SVP, Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| AKBA | SELL | 2024-02-29 | $16K | — | Filing → |
| AKBA | SELL | 2023-05-25 | $233K | — | Filing → |
| AKBA | SELL | 2023-03-03 | $18K | — | Filing → |